COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01764425
Recruitment Status : Terminated
First Posted : January 9, 2013
Last Update Posted : July 9, 2013
Information provided by (Responsible Party):
Piramal Enterprises Limited

Brief Summary:
Clinical trial to study the safety tolerability, pharmacokinetics, food effect and pharmacodynamics of a new compound P7435 in in healthy, overweight and/or obese subjects

Condition or disease Intervention/treatment Phase
Healthy, Overweight and/or Obese Subjects Drug: P7435 Phase 1

Detailed Description:
  • A phase I, randomized, double-blind, placebo-controlled, dose escalating study of P7435 to determine the safety, tolerability, pharmacokinetics, food effect and pharmacodynamics of single and multiple ascending doses of P7435.
  • Subjects participating will be either healthy subjects or healthy overweight and/or obese subjects. In this study, overweight/obese are defined as subjects having a BMI of 23 kg/m2 and above.
  • The study will be conducted in 3 parts as follows: Part A will consist of the Single Ascending Dose (SAD) study, Part B will consist of the Multiple Ascending Dose (MAD) study and Part C will consist of the Food Effect study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I, Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight and/or Obese Subjects
Study Start Date : May 2012
Actual Primary Completion Date : September 2012
Actual Study Completion Date : February 2013

Arm Intervention/treatment
Active Comparator: P7435
Tablets for once daily oral administration, For SAD part of the study dose would be 10 mg for Cohort 1; Cohorts 2, 3, 4 and 5 will be dosed subsequently at 30 mg, 100 mg, 300 mg, 1000 mg respectively Dose for MAD and food effects part of the study would be based on SAD study results
Drug: P7435
It is oral DGATI inhibitor with potential in dyslipidemia and T2DM

Placebo Comparator: Placebo
Placebo tablets for oral administration
Drug: P7435
It is oral DGATI inhibitor with potential in dyslipidemia and T2DM

Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: Up to Day 5 ]
    - Number of participants with adverse events in the single and multiple ascending dose studies.

  2. Effect of food on drug concentrations [ Time Frame: Day 1 ]

Secondary Outcome Measures :
  1. Pharmacokinetics profile (Cmax, Tmax, and AUC) [ Time Frame: Day 1 and Day 14 ]
    • The PK profile will be derived from the P7435 plasma concentration data.
    • A non compartmental model will be used to analyze the plasma levels of P7435

Other Outcome Measures:
  1. Change from baseline in fasting glucose, insulin, C-peptide and lipids [ Time Frame: Day 1 and Day 14 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Willingness and are able to provide a written informed consent to participate in the study.
  • Healthy adult male subjects aged between 18 and 45 (both inclusive) years old
  • BMI between 19 and 23 kg/m2. Overweight (BMI between 23 and 25kg/m2) and/or obese (BMI between 25 and 35 kg/m2) but otherwise healthy subjects in PartB .
  • Healthy as determined by the investigator
  • Smoking less than 10 cigarettes per day and able to refrain from smoking during confinement.
  • Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, coke, chocolate, "power drinks") and grapefruit juice to admission.

Exclusion Criteria:

  • Employees of the sponsor or clinical sites.
  • Female subjects.
  • No past or current serious diseases of any organ will be allowed. Exceptions may be non-malignant skin diseases, childhood asthma and other conditions as per the Investigator's discretion and discussed with the Sponsor a priori. History of significant gastrointestinal disease or other significant diseases including cardiac, renal or liver impairment.
  • History of sleep apnea, irregular sleep/wake cycle or working in night shifts.
  • Acute disease state
  • History of hypo/hyperthyroidism or repeated abnormal TSH values at screening or obesity of endocrine origin.
  • History of alcoholism for more than 2 years
  • Positive serology for human immunodeficiency virus (HIV-1/2) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.
  • Positive findings in urine drug screen / alcohol breath test.
  • Participation in another clinical trial within 90 days of the first drug administration.
  • Intake of more than 8-10 cups of coffee and/or tea per day and consumption of methyl xanthine-containing beverages (tea, coffee, cola drinks, chocolate) within 48 hours prior to study.
  • Donation of blood (i.e. 350 ml) within 90 days before Day -1 of the first treatment period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01764425

Layout table for location information
Piramal Clinical Research
Hyderabad, Andhra Pradesh, India, 500013
Veeda Clinical Research
Ahmedabad, Gujarat, India, 380015
Sponsors and Collaborators
Piramal Enterprises Limited
Layout table for investigator information
Principal Investigator: Dr Madhavi Latha Kodru
Principal Investigator: Dr Dharmesh Domadia
Layout table for additonal information
Responsible Party: Piramal Enterprises Limited Identifier: NCT01764425    
Other Study ID Numbers: P7435/66/11
First Posted: January 9, 2013    Key Record Dates
Last Update Posted: July 9, 2013
Last Verified: July 2013
Keywords provided by Piramal Enterprises Limited:
Healthy,overweight and or obese subjects
Single ascending dose
Multiple ascending dose
Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight